GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (LTS:0NZU) » Definitions » Cyclically Adjusted Revenue per Share

Zealand Pharma A/S (LTS:0NZU) Cyclically Adjusted Revenue per Share : kr5.30 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zealand Pharma A/S's adjusted revenue per share for the three months ended in Mar. 2024 was kr0.245. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr5.30 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Zealand Pharma A/S's average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zealand Pharma A/S was -3.90% per year. The lowest was -7.60% per year. And the median was -5.75% per year.

As of today (2024-06-05), Zealand Pharma A/S's current stock price is kr615.25. Zealand Pharma A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr5.30. Zealand Pharma A/S's Cyclically Adjusted PS Ratio of today is 116.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zealand Pharma A/S was 132.23. The lowest was 13.51. And the median was 35.13.


Zealand Pharma A/S Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Zealand Pharma A/S's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Cyclically Adjusted Revenue per Share Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.50 6.33 5.78 5.18 5.64

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.10 5.04 5.65 5.64 5.30

Competitive Comparison of Zealand Pharma A/S's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Zealand Pharma A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Cyclically Adjusted PS Ratio falls into.



Zealand Pharma A/S Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zealand Pharma A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.245/118.4000*118.4000
=0.245

Current CPI (Mar. 2024) = 118.4000.

Zealand Pharma A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.190 99.700 0.226
201409 2.553 99.700 3.032
201412 0.274 99.400 0.326
201503 0.280 100.200 0.331
201506 0.316 100.300 0.373
201509 0.314 100.200 0.371
201512 7.067 99.800 8.384
201603 0.283 100.200 0.334
201606 0.332 100.600 0.391
201609 1.649 100.200 1.949
201612 6.915 100.300 8.163
201703 2.969 101.200 3.474
201706 0.390 101.200 0.456
201709 1.373 101.800 1.597
201712 0.329 101.300 0.385
201803 0.317 101.700 0.369
201806 0.493 102.300 0.571
201809 0.000 102.400 0.000
201812 0.427 102.100 0.495
201903 0.000 102.900 0.000
201906 0.629 102.900 0.724
201909 0.302 102.900 0.347
201912 0.315 102.900 0.362
202003 0.344 103.300 0.394
202006 5.948 103.200 6.824
202009 1.424 103.500 1.629
202012 -2.415 103.400 -2.765
202103 0.135 104.300 0.153
202106 0.846 105.000 0.954
202109 1.256 105.800 1.406
202112 0.311 106.600 0.345
202203 0.254 109.900 0.274
202206 0.574 113.600 0.598
202209 0.946 116.400 0.962
202212 0.469 115.900 0.479
202303 0.265 117.300 0.267
202306 0.179 116.400 0.182
202309 4.902 117.400 4.944
202312 0.398 116.700 0.404
202403 0.245 118.400 0.245

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Zealand Pharma A/S  (LTS:0NZU) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zealand Pharma A/S's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=615.25/5.3
=116.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zealand Pharma A/S was 132.23. The lowest was 13.51. And the median was 35.13.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zealand Pharma A/S Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (LTS:0NZU) Business Description

Industry
Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (LTS:0NZU) Headlines

No Headlines